Some curves can be navigated with a slight adjustment. Others demand greater attention and adaptability.
There were several of the latter in the pharmaceutical ecosystem in 2025–26, including evolving market dynamics and various domestic and international policy developments with potentially global implications.
Continuing to navigate this will require us to make thoughtful decisions without a full picture of what lies ahead and remain ready to respond as new information comes into view. Importantly, navigating the shifting global landscape isn’t something we should do alone.
In fact, one way we’re reinforcing our ability to navigate uncertainty is by broadening our field of view and learning from others. Around the world, governments and pricing organizations are responding to many of the same pressures. Over the last fiscal year, we worked to build relationships with international peers. We continue to foster these relationships to benchmark, exchange knowledge, and collaborate as we all think through best approaches to support governments and populations. This will help us test ideas against global experience and ensure our decisions are grounded in both Canadian priorities and global insight.
Broadening our field of view... will help us test ideas against global experience and ensure our decisions are grounded in both Canadian priorities and global insight.
